The value of the simplified RAMRIS-5 in early RA patients under methotrexate therapy using high-field MRI.
Early rheumatoid arthritis
High-field magnetic resonance imaging
Prediction
RAMRIS
RAMRIS-5
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
14 01 2019
14 01 2019
Historique:
received:
11
05
2018
accepted:
07
12
2018
entrez:
16
1
2019
pubmed:
16
1
2019
medline:
31
3
2020
Statut:
epublish
Résumé
The aim of the study was to evaluate a simplified version of the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) for five joints of the hand (RAMRIS-5) in patients with early rheumatoid arthritis (RA) before and after the initiation of methotrexate (MTX) therapy using high-resolution, 3-T magnetic resonance imaging (MRI). Twenty-eight patients with a seropositive, early RA (disease duration of less than 6 months (range 2-23 weeks)) according to 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria (mean age 56.8 years, range 39-74) were prospectively assessed with a baseline investigation including clinical assessment (disease activity score of 28 joints (DAS-28) and C-reactive protein (CRP)) and 3-T MRI of the clinically dominant hand. Follow-up visits were performed 3 and 6 months after initiation of a MTX therapy at baseline. MRI scans were analyzed in accordance with RAMRIS and the simplified RAMRIS-5. DAS-28 and CRP decreased significantly after initiation of MTX therapy. Even though erosion scores increased over time, RAMRIS and RAMRIS-5 also decreased significantly after the start of therapy. There was a strong correlation between the total RAMRIS-5 and RAMRIS at baseline (r = 0.838; P <0.001) and follow-up (3 months: r = 0.876; P <0.001; 6 months: r = 0.897; P <0.001). In the short term (3-month follow-up), RAMRIS and RAMRIS-5 demonstrated similar ability to detect changes for all subgroups (bone edema, erosion, and synovitis). In the long-term comparison (6-month follow-up), RAMRIS-5 also showed similar effectiveness when detecting changes in bone edema and erosion compared with RAMRIS. Deviations occurred regarding only synovitis, where change was slightly higher in RAMRIS-5: SRM (RAMRIS) = 0.07 ± 0.14; SRM (RAMRIS-5) = 0.34 ± 0.06. Three-Tesla MRI-based RAMRIS-5 is a simplified and resource-saving RAMRIS score which compares favorably with the RAMRIS when detecting changes in early RA. Even though there is a slight abbreviation between RAMRIS-5 and the original score regarding the change of synovitis, it may be used for diagnosis and therapy monitoring in follow-up evaluations.
Sections du résumé
BACKGROUND
The aim of the study was to evaluate a simplified version of the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) for five joints of the hand (RAMRIS-5) in patients with early rheumatoid arthritis (RA) before and after the initiation of methotrexate (MTX) therapy using high-resolution, 3-T magnetic resonance imaging (MRI).
METHODS
Twenty-eight patients with a seropositive, early RA (disease duration of less than 6 months (range 2-23 weeks)) according to 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria (mean age 56.8 years, range 39-74) were prospectively assessed with a baseline investigation including clinical assessment (disease activity score of 28 joints (DAS-28) and C-reactive protein (CRP)) and 3-T MRI of the clinically dominant hand. Follow-up visits were performed 3 and 6 months after initiation of a MTX therapy at baseline. MRI scans were analyzed in accordance with RAMRIS and the simplified RAMRIS-5.
RESULTS
DAS-28 and CRP decreased significantly after initiation of MTX therapy. Even though erosion scores increased over time, RAMRIS and RAMRIS-5 also decreased significantly after the start of therapy. There was a strong correlation between the total RAMRIS-5 and RAMRIS at baseline (r = 0.838; P <0.001) and follow-up (3 months: r = 0.876; P <0.001; 6 months: r = 0.897; P <0.001). In the short term (3-month follow-up), RAMRIS and RAMRIS-5 demonstrated similar ability to detect changes for all subgroups (bone edema, erosion, and synovitis). In the long-term comparison (6-month follow-up), RAMRIS-5 also showed similar effectiveness when detecting changes in bone edema and erosion compared with RAMRIS. Deviations occurred regarding only synovitis, where change was slightly higher in RAMRIS-5: SRM (RAMRIS) = 0.07 ± 0.14; SRM (RAMRIS-5) = 0.34 ± 0.06.
CONCLUSIONS
Three-Tesla MRI-based RAMRIS-5 is a simplified and resource-saving RAMRIS score which compares favorably with the RAMRIS when detecting changes in early RA. Even though there is a slight abbreviation between RAMRIS-5 and the original score regarding the change of synovitis, it may be used for diagnosis and therapy monitoring in follow-up evaluations.
Identifiants
pubmed: 30642376
doi: 10.1186/s13075-018-1789-3
pii: 10.1186/s13075-018-1789-3
pmc: PMC6332674
doi:
Substances chimiques
Antirheumatic Agents
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 01EC1009
Pays : International
Références
Muscles Ligaments Tendons J. 2015 Mar 27;5(1):12-7
pubmed: 25878981
AJR Am J Roentgenol. 2004 Apr;182(4):937-43
pubmed: 15039167
Ann Rheum Dis. 2013 Jun;72(6):804-14
pubmed: 23520036
J Rheumatol. 2002 Nov;29(11):2278-87
pubmed: 12415582
BMC Musculoskelet Disord. 2011 Jun 06;12:128
pubmed: 21645348
Ann Rheum Dis. 2017 Jun;76(6):948-959
pubmed: 27979873
Ann Rheum Dis. 2007 Jan;66(1):34-45
pubmed: 16396980
Arthritis Res Ther. 2006;8(6):222
pubmed: 17169137
Clin Exp Rheumatol. 2015 Mar-Apr;33(2):209-15
pubmed: 25664925
Ann Rheum Dis. 2018 Jun;77(6):861-868
pubmed: 29490980
Ann Rheum Dis. 2014 Nov;73(11):1968-74
pubmed: 23904470
Ann Rheum Dis. 2018 Jan;77(1):111-118
pubmed: 28970207
J Rheumatol. 2003 Jun;30(6):1385-6
pubmed: 12784422
Ann Rheum Dis. 2010 Sep;69(9):1580-8
pubmed: 20699241
Ther Adv Musculoskelet Dis. 2016 Aug;8(4):107-18
pubmed: 27493689
Eur Radiol. 2000;10(6):989-96
pubmed: 10879716
Arthritis Rheum. 2011 Dec;63(12):3712-22
pubmed: 22127693
Eur Radiol. 1999;9(5):998-1004
pubmed: 10370005
Ann Rheum Dis. 1976 Aug;35(4):361-4
pubmed: 970995
Ann Rheum Dis. 2005 Sep;64(9):1280-7
pubmed: 15650012
Arthritis Res Ther. 2015 Aug 03;17:197
pubmed: 26235697
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
Rheumatology (Oxford). 2004 Jul;43(7):906-14
pubmed: 15113999
BMC Musculoskelet Disord. 2017 Apr 19;18(1):163
pubmed: 28420375
Ann Rheum Dis. 2005 Feb;64 Suppl 1:i3-7
pubmed: 15647420
BMC Musculoskelet Disord. 2014 Mar 26;15:104
pubmed: 24669889
Eur Radiol. 2007 Aug;17(8):2176-82
pubmed: 17219147
Radiology. 2010 Sep;256(3):863-9
pubmed: 20663972
Clin Rheumatol. 2007 Jul;26(7):1111-8
pubmed: 17109060